ING Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.2M | Sell |
65,425
-15,704
| -19% | -$7.32M | 0.18% | 98 |
|
|
2025
Q4 | $36.8M | Buy |
81,129
+69,140
| +577% | +$29.8M | 0.22% | 92 |
|
|
2025
Q3 | $4.7M | Buy |
+11,989
| New | +$5.01M | 0.03% | 280 |
|
|
2025
Q1 | – | Sell |
-4,784
| Closed | -$1.93M | – | 611 |
|
|
2024
Q4 | $1.93M | Sell |
4,784
-48,754
| -91% | -$22.6M | 0.01% | 413 |
|
|
2024
Q3 | $24.9M | Sell |
53,538
-12,587
| -19% | -$6.05M | 0.14% | 112 |
|
|
2024
Q2 | $31M | Sell |
66,125
-10,918
| -14% | -$4.74M | 0.18% | 99 |
|
|
2024
Q1 | $32.2M | Buy |
77,043
+1,945
| +3% | +$822K | 0.22% | 86 |
|
|
2023
Q4 | $30.6M | Sell |
75,098
-10,060
| -12% | -$3.72M | 0.25% | 76 |
|
|
2023
Q3 | $29.6M | Buy |
85,158
+6,745
| +9% | +$2.36M | 0.26% | 81 |
|
|
2023
Q2 | $27.6M | Buy |
78,413
+34,115
| +77% | +$11.5M | 0.21% | 90 |
|
|
2023
Q1 | $14M | Buy |
+44,298
| New | +$13.3M | 0.14% | 131 |
|
|
2022
Q4 | – | Sell |
-60,025
| Closed | -$17.4M | – | 569 |
|
|
2022
Q3 | $17.4M | Buy |
60,025
+3,056
| +5% | +$879K | 0.29% | 76 |
|
|
2022
Q2 | $16.1M | Buy |
56,969
+45,788
| +410% | +$12.3M | 0.19% | 96 |
|
|
2022
Q1 | $2.92M | Sell |
11,181
-32,806
| -75% | -$7.79M | 0.03% | 343 |
|
|
2021
Q4 | $9.66M | Buy |
43,987
+17,641
| +67% | +$3.43M | 0.09% | 181 |
|
|
2021
Q3 | $4.78M | Buy |
26,346
+520
| +2% | +$102K | 0.06% | 203 |
|
|
2021
Q2 | $5.21M | Buy |
25,826
+8,614
| +50% | +$1.8M | 0.08% | 157 |
|
|
2021
Q1 | $3.7M | Sell |
17,212
-36
| -0.2% | -$7.91K | 0.08% | 161 |
|
|
2020
Q4 | $4.08M | Buy |
17,248
+11,483
| +199% | +$2.63M | 0.09% | 151 |
|
|
2020
Q3 | $1.57M | Buy |
5,765
+3,572
| +163% | +$985K | 0.06% | 147 |
|
|
2020
Q2 | $637K | Sell |
2,193
-10,507
| -83% | -$2.85M | 0.03% | 154 |
|
|
2020
Q1 | $3.02M | Buy |
12,700
+11,062
| +675% | +$2.54M | 0.13% | 102 |
|
|
2019
Q4 | $359K | Sell |
1,638
-14,405
| -90% | -$2.92M | 0.01% | 427 |
|
|
2019
Q3 | $2.72M | Sell |
16,043
-60,256
| -79% | -$10.7M | 0.07% | 183 |
|
|
2019
Q2 | $14M | Buy |
76,299
+434
| +0.6% | +$75.9K | 0.24% | 78 |
|
|
2019
Q1 | $14M | Buy |
75,865
+8,916
| +13% | +$1.65M | 0.3% | 61 |
|
|
2018
Q4 | $11.1M | Buy |
66,949
+42,491
| +174% | +$7.36M | 0.24% | 73 |
|
|
2018
Q3 | $4.71M | Sell |
24,458
-10,793
| -31% | -$1.92M | 0.08% | 164 |
|
|
2018
Q2 | $5.99M | Sell |
35,251
-8,585
| -20% | -$1.33M | 0.11% | 109 |
|
|
2018
Q1 | $7.14M | Sell |
43,836
-13,544
| -24% | -$2.21M | 0.13% | 100 |
|
|
2017
Q4 | $8.6M | Buy |
57,380
+11,506
| +25% | +$1.7M | 0.14% | 79 |
|
|
2017
Q3 | $6.97M | Sell |
45,874
-8,979
| -16% | -$1.35M | 0.13% | 116 |
|
|
2017
Q2 | $7.07M | Buy |
54,853
+9,157
| +20% | +$1.1M | 0.14% | 104 |
|
|
2017
Q1 | $5M | Buy |
45,696
+38,280
| +516% | +$3.37M | 0.09% | 144 |
|
|
2016
Q4 | $552K | Sell |
7,416
-2,019
| -21% | -$164K | 0.01% | 412 |
|
|
2016
Q3 | $802K | Buy |
9,435
+7,059
| +297% | +$667K | 0.01% | 316 |
|
|
2016
Q2 | $204K | Buy |
+2,376
| New | +$205K | ﹤0.01% | 500 |
|
|
2015
Q2 | – | Sell |
-9,520
| Closed | -$1.12M | – | 739 |
|
|
2015
Q1 | $1.12M | Buy |
9,520
+70
| +0.7% | +$8.39K | 0.01% | 580 |
|
|
2014
Q4 | $1.12M | Buy |
+9,450
| New | +$1.06M | 0.01% | 557 |
|
|
2013
Q4 | – | Sell |
-240,413
| Closed | -$18.2M | – | 781 |
|
|
2013
Q3 | $18.2M | Buy |
+240,413
| New | +$19.1M | 0.09% | 219 |
|
Other funds holding VRTX
VCM
VPM
ING Group's VRTX Position: Q1 2026 in Review
ING Group reduced its Vertex Pharmaceuticals (VRTX) stake by 19% in Q1 2026, selling an estimated $7.32M and leaving 65,425 shares worth $29.2M. The position accounts for 0.18% of the portfolio, ranked #98.
ING Group first reported a position in VRTX in Q3 2013 and has held it in 40 quarters since. The position peaked at $36.8M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- ING Group held 65,425 shares of Vertex Pharmaceuticals worth $29.2M as of Q1 2026.
- ING Group sold 15,704 Vertex Pharmaceuticals shares in Q1 2026, an estimated $7.32M.
- Vertex Pharmaceuticals made up 0.18% of ING Group's portfolio in Q1 2026, its #98 holding.
- ING Group first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 40 quarters since.
- ING Group's Vertex Pharmaceuticals position peaked at $36.8M in Q4 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on ING Group's 13F filing for Q1 2026, filed 11 May 2026.